Literature DB >> 1329495

Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis.

R S Izzo1, K Witkon, A I Chen, C Hadjiyane, M I Weinstein, C Pellecchia.   

Abstract

In this study, mediators of inflammation were characterized in colonic and terminal ileum mucosa from subjects with ulcerative colitis. We considered the role of two different chemotactic factors (interleukin-8 and leukotriene B4) and of myeloperoxidase in the pathology of inflammatory bowel disease. Serial biopsy specimens were taken at different sites, washed in 0.02 M phosphate/saline buffer, homogenized, and then sonically disrupted. In both the proximal and distal regions of the colonic mucosa of ulcerative colitis patients, there was a more than 10-fold increase in interleukin-8 levels over that in control subjects (> 300 pg/mg protein vs. 30 pg/mg protein in controls, p < or = 0.01). However, terminal ileum levels of interleukin-8 were the same in ulcerative colitis and control groups (150 pg/mg protein). There was also a 3- to 5-fold increase in leukotriene B4 levels and a several-fold increase in myeloperoxidase levels throughout the colonic mucosa in patients with ulcerative colitis. This study demonstrates that 1) interleukin-8 may have an immunoregulatory role in the pathogenesis of inflammatory bowel disease, and 2) interleukin-8, myeloperoxidase, and leukotriene B4 may be useful markers for the biochemical identification of inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329495

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  29 in total

1.  Eosinophil granulocytes are activated during the remission phase of ulcerative colitis.

Authors:  M Lampinen; A Rönnblom; K Amin; G Kristjansson; F Rorsman; P Sangfelt; B Säfsten; M Wagner; A Wanders; O Winqvist; M Carlson
Journal:  Gut       Date:  2005-05-10       Impact factor: 23.059

2.  Increased circulating concentrations of growth-related oncogene (GRO)-alpha in patients with inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Osamu Tsuruta; Nobuo Tomiyasu; Kosuke Takaki; Asuka Suzuki; Junya Masuda; Hiroshi Yamasaki; Atsushi Toyonaga; Michio Sata
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

3.  Neutrophil differentiated HL-60 cells model Mac-1 (CD11b/CD18)-independent neutrophil transepithelial migration.

Authors:  Svetlana O Carrigan; Amy L Weppler; Andrew C Issekutz; Andrew W Stadnyk
Journal:  Immunology       Date:  2005-05       Impact factor: 7.397

4.  Transcriptional and post-transcriptional regulation of interleukin-8.

Authors:  L H Villarete; D G Remick
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

5.  Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli virulence factors in international travelers.

Authors:  Zhi-Dong Jiang; David Greenberg; James P Nataro; Robert Steffen; Herbert L DuPont
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

6.  Augmented expression of secondary lymphoid tissue chemokine and EBI1 ligand chemokine in Crohn's disease.

Authors:  D Kawashima; N Oshitani; Y Jinno; K Watanabe; S Nakamura; K Higuchi; T Arakawa
Journal:  J Clin Pathol       Date:  2005-10       Impact factor: 3.411

Review 7.  Chemokines in the inflammatory bowel diseases.

Authors:  R P MacDermott
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

8.  The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment.

Authors:  Rudolf Schicho; Mohammad Bashashati; Misha Bawa; Douglas McHugh; Dieter Saur; Huang-Ming Hu; Andreas Zimmer; Beat Lutz; Ken Mackie; Heather B Bradshaw; Donna-Marie McCafferty; Keith A Sharkey; Martin Storr
Journal:  Inflamm Bowel Dis       Date:  2010-11-15       Impact factor: 5.325

9.  Persistence of local cytokine production in shigellosis in acute and convalescent stages.

Authors:  R Raqib; A A Lindberg; B Wretlind; P K Bardhan; U Andersson; J Andersson
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

10.  Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease.

Authors:  Michael Wagner; Christer G B Peterson; Peter Ridefelt; Per Sangfelt; Marie Carlson
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.